Residual risks by ethnicity
|
|
- Corey Lawson
- 5 years ago
- Views:
Transcription
1 Residual risks by ethnicity This table displays residual risks after a negative result for each of the genes and corresponding disorders. If a patient is reported to be a carrier of a disease, their residual risk is 1 and this table does not apply for that disease. Disease (Inheritance) Gene Ethnicity Carrier Frequency Detection Rate Residual Risk Analytical Detection Rate Abetalipoproteinemia (AR) MTTP African 1 in % 1 in 45,000 97% NM_ Ashkenazi Jewish 1 in % 1 in 5,800 East Asian 1 in % 1 in 7,500 Caucasian 1 in % 1 in 3,200 Latino 1 in % 1 in 71,000 South Asian 1 in % 1 in 103,000 Worldwide 1 in % 1 in 5,900 Achromatopsia (AR) CNGB3 African 1 in 50 98% 1 in 2,300 99% NM_ Ashkenazi Jewish 1 in 97 99% 1 in 9,600 East Asian 1 in % 1 in 20,700 Finnish 1 in % 1 in 16,200 Caucasian 1 in 87 99% 1 in 8,600 Latino 1 in 90 99% 1 in 8,900 South Asian 1 in 18 99% 1 in 1,700 Worldwide 1 in 61 99% 1 in 4,300 Acrodermatitis Enteropathica (AR) SLC39A4 African 1 in % 1 in 21,000 98% NM_ East Asian 1 in % 1 in 62,400 Finnish 1 in % 1 in 10,800 Caucasian 1 in % 1 in 12,100 Latino 1 in % 1 in 13,500 South Asian 1 in % 1 in 54,900 Worldwide 1 in % 1 in 11,000 Acute Infantile Liver Failure (AR) TRMU African 1 in % 1 in 5,500 99% NM_ Ashkenazi Jewish 1 in % 1 in 45,900 East Asian 1 in % 1 in 55,000 Caucasian 1 in % 1 in 9,400 Latino 1 in % 1 in 116,000 South Asian 1 in % 1 in 1,500 Worldwide 1 in % 1 in 6,600 Sephardic Jewish - Yemenite 1 in 34 81% 1 in 180 Acyl-CoA Oxidase I Deficiency (AR) ACOX1 African 1 in % 1 in 42,800 98% NM_ Caucasian 1 in % 1 in 35,800 Latino 1 in % 1 in 134,000 South Asian 1 in % 1 in 154,000 Worldwide 1 in % 1 in 52,000 Adenosine Deaminase Deficiency (AR) ADA African 1 in 91 92% 1 in 1,200 99% NM_ East Asian 1 in % 1 in 127,000 Finnish 1 in % 1 in 430,000 Caucasian 1 in % 1 in 5,100 Latino 1 in % 1 in 5,700 South Asian 1 in % 1 in 2,100 Worldwide 1 in % 1 in 3,300 Adrenoleukodystrophy, X-Linked (XL) ABCD1 Worldwide 1 in 10,000 47% 1 in 18,900 89% NM_ Exception: Exons 8 and 9
2 Aicardi-Goutières Syndrome SAMHD1 African 1 in % 1 in 75,300 99% (SAMHD1-Related) (AR) Ashkenazi Jewish 1 in % 1 in 12,900 NM_ East Asian 1 in % 1 in 2,700 Caucasian 1 in % 1 in 10,100 Latino 1 in % 1 in 241,000 South Asian 1 in % 1 in 385,000 Worldwide 1 in % 1 in 13,200 Alpha-Mannosidosis (AR) MAN2B1 African 1 in % 1 in 29,000 99% NM_ East Asian 1 in % 1 in 8,000 Finnish 1 in % 1 in 21,800 Caucasian 1 in % 1 in 6,200 Latino 1 in % 1 in 5,200 South Asian 1 in % 1 in 2,500 Worldwide 1 in % 1 in 6,000 Alpha-Thalassemia (AR) HBA1 / HBA2 Caucasian 1 in % 1 in 10,000 99% NM_ / NM_ African American 1 in 30 95% 1 in 580 Asian 1 in 20 95% 1 in 380 Worldwide 1 in 25 95% 1 in 480 Alpha-Thalassemia Mental Retardation ATRX Worldwide 1 in 20,000 58% 1 in 45,000 98% Syndrome (XL) NM_ Alport Syndrome (COL4A3-Related) (AR) COL4A3 African 1 in % 1 in 2,200 99% NM_ Ashkenazi Jewish 1 in % 1 in 22,600 East Asian 1 in % 1 in 1,700 Finnish 1 in % 1 in 5,300 Caucasian 1 in % 1 in 1,800 Latino 1 in % 1 in 1,600 South Asian 1 in % 1 in 3,500 Worldwide 1 in % 1 in 2,100 Alport Syndrome (COL4A4-Related) (AR) COL4A4 African 1 in % 1 in 1,500 98% NM_ Ashkenazi Jewish 1 in % 1 in 82,000 East Asian 1 in % 1 in 510 Finnish 1 in % 1 in 142,000 Caucasian 1 in % 1 in 1,800 Latino 1 in % 1 in 5,800 South Asian 1 in % 1 in 5,700 Worldwide 1 in % 1 in 1,800 Alport Syndrome (COL4A5-Related) (XL) COL4A5 Worldwide 1 in 30,000 80% 1 in 16,400 94% NM_ Alstrom Syndrome (AR) ALMS1 African 1 in % 1 in 2,300 99% NM_ East Asian 1 in % 1 in 3,100 Finnish 1 in % 1 in 62,500 Caucasian 1 in % 1 in 4,500 Latino 1 in % 1 in 35,100 South Asian 1 in % 1 in 3,400 Worldwide 1 in % 1 in 5,100
3 Andermann Syndrome (AR) SLC12A6 Ashkenazi Jewish 1 in % 1 in 164,000 99% NM_ East Asian 1 in % 1 in 287,000 Finnish 1 in % 1 in 279,000 Caucasian 1 in % 1 in 151,000 Latino 1 in % 1 in 76,300 South Asian 1 in % 1 in 256,000 Worldwide 1 in % 1 in 161,000 French-Canadian - 1 in 23 99% 1 in 2,200 Saguenay Lac-St. Jean Argininosuccinic Aciduria (AR) ASL African 1 in % 1 in 1,300 99% NM_ Ashkenazi Jewish 1 in % 1 in 56,000 East Asian 1 in % 1 in 4,000 Finnish 1 in 91 99% 1 in 9,000 Caucasian 1 in % 1 in 1,200 Latino 1 in % 1 in 1,500 South Asian 1 in % 1 in 2,900 Worldwide 1 in % 1 in 1,300 Aromatase Deficiency (AR) CYP19A1 African 1 in % 1 in 4,200 89% NM_ Ashkenazi Jewish 1 in % 1 in 5,800 East Asian 1 in % 1 in 1,200 Finnish 1 in % 1 in 7,400 Caucasian 1 in % 1 in 5,400 Latino 1 in % 1 in 9,200 South Asian 1 in % 1 in 4,200 Worldwide 1 in % 1 in 3,900 Arthrogryposis, Mental Retardation, SLC35A3 African 1 in % 1 in 400,000 99% and Seizures (AR) Ashkenazi Jewish 1 in % 1 in 36,600 NM_ Finnish 1 in % 1 in 278,000 Caucasian 1 in % 1 in 454,000 Latino 1 in % 1 in 336,000 South Asian 1 in % 1 in 399,000 Worldwide 1 in % 1 in 240,000 Asparagine Synthetase Deficiency (AR) ASNS African 1 in % 1 in 84,400 99% NM_ East Asian 1 in % 1 in 178,000 Finnish 1 in % 1 in 3,700 Caucasian 1 in % 1 in 23,900 South Asian 1 in % 1 in 307,000 Worldwide 1 in % 1 in 20,900 Sephardic Jewish - Iranian 1 in 80 99% 1 in 8,100 Aspartylglycosaminuria (AR) AGA African 1 in % 1 in 165,000 99% NM_ East Asian 1 in % 1 in 172,000 Finnish 1 in 60 98% 1 in 3,800 Caucasian 1 in % 1 in 13,000 Latino 1 in % 1 in 15,300 South Asian 1 in % 1 in 220,000 Worldwide 1 in % 1 in 12,800 Ataxia with Isolated Vitamin E Deficiency (AR) TTPA African 1 in % 1 in 31,800 99% NM_ Ashkenazi Jewish 1 in % 1 in 51,200 Finnish 1 in % 1 in 310,000 Caucasian 1 in % 1 in 60,600 Latino 1 in % 1 in 129,000 South Asian 1 in % 1 in 240,000 Worldwide 1 in % 1 in 19,500
4 Ataxia Telangiectasia (AR) ATM African 1 in % 1 in 1,400 95% NM_ Ashkenazi Jewish 1 in % 1 in 3,900 East Asian 1 in % 1 in 540 Finnish 1 in % 1 in 1,300 Caucasian 1 in % 1 in 1,300 Latino 1 in % 1 in 2,700 South Asian 1 in % 1 in 900 Worldwide 1 in % 1 in 1,200 Autosomal Recessive Spastic Ataxia SACS African 1 in % 1 in 20,000 99% of Charlevoix-Saguenay (AR) Ashkenazi Jewish 1 in % 1 in 2,400 NM_ East Asian 1 in % 1 in 2,100 Finnish 1 in % 1 in 34,000 Caucasian 1 in % 1 in 2,100 Latino 1 in % 1 in 2,600 South Asian 1 in % 1 in 11,000 Worldwide 1 in % 1 in 2,900 French Canadian - 1 in 21 99% 1 in 2,000 Charlevoix-Saguenay Bardet-Biedl Syndrome (BBS1-Related) (AR) BBS1 African 1 in % 1 in 3,900 99% NM_ East Asian 1 in % 1 in 2,200 Finnish 1 in % 1 in 27,100 Caucasian 1 in % 1 in 5,400 Latino 1 in % 1 in 41,600 South Asian 1 in % 1 in 8,400 Worldwide 1 in % 1 in 6,200 Faroese 1 in 30 99% 1 in 2,900 Bardet-Biedl Syndrome (BBS2-Related) (AR) BBS2 African 1 in % 1 in 6,900 99% NM_ Ashkenazi Jewish 1 in % 1 in 1,500 East Asian 1 in % 1 in 5,400 Finnish 1 in % 1 in 44,100 Caucasian 1 in % 1 in 1,200 Latino 1 in % 1 in 2,800 South Asian 1 in % 1 in 13,100 Worldwide 1 in % 1 in 2,000 Hutterite 1 in 22 99% 1 in 2,100 Bardet-Biedl Syndrome (BBS10-Related) (AR) BBS10 African 1 in % 1 in 9,600 99% NM_ Ashkenazi Jewish 1 in % 1 in 29,700 East Asian 1 in % 1 in 2,100 Caucasian 1 in % 1 in 2,700 Latino 1 in % 1 in 5,400 South Asian 1 in % 1 in 1,400 Worldwide 1 in % 1 in 3,000 Bardet-Biedl Syndrome (BBS12-Related) (AR) BBS12 African 1 in % 1 in 7,100 99% NM_ East Asian 1 in % 1 in 287,000 Caucasian 1 in % 1 in 9,900 Latino 1 in % 1 in 186,000 South Asian 1 in % 1 in 170,000 Worldwide 1 in % 1 in 17,200 Bare Lymphocyte Syndrome, Type II (AR) CIITA African 1 in % 1 in 336,000 99% NM_ East Asian 1 in % 1 in 129,000 Caucasian 1 in % 1 in 34,800 Latino 1 in % 1 in 240,000 South Asian 1 in % 1 in 220,000 Worldwide 1 in % 1 in 64,700
5 Bartter Syndrome, Type 4A (AR) BSND African 1 in % 1 in 5,400 99% NM_ Ashkenazi Jewish 1 in % 1 in 164,000 East Asian 1 in % 1 in 68,600 Caucasian 1 in % 1 in 91,500 Latino 1 in % 1 in 286,000 South Asian 1 in % 1 in 73,200 Worldwide 1 in % 1 in 46,300 Bernard-Soulier Syndrome, Type A1 (AR) GP1BA African 1 in % 1 in 203,000 99% NM_ East Asian 1 in % 1 in 172,000 Finnish 1 in % 1 in 36,700 Caucasian 1 in % 1 in 42,200 Latino 1 in % 1 in 420,000 Worldwide 1 in % 1 in 66,200 Bernard-Soulier Syndrome, Type C (AR) GP9 African 1 in % 1 in % NM_ Finnish 1 in % 1 in 710 Caucasian 1 in % 1 in 3,300 Latino 1 in % 1 in 16,300 South Asian 1 in % 1 in 84,700 Worldwide 1 in % 1 in 1,100 Beta-Globin Related Hemoglobinopathies: HBB African 1 in 97 92% 1 in 1,200 99% Beta-Thalassemia (AR) Ashkenazi Jewish 1 in 28 99% 1 in 2,700 NM_ East Asian 1 in 87 93% 1 in 1,200 Finnish 1 in % 1 in 3,700 Caucasian 1 in % 1 in 2,000 Latino 1 in % 1 in 3,900 South Asian 1 in 25 98% 1 in 1,000 Worldwide 1 in 81 95% 1 in 1,800 Mediterranean 1 in 28 99% 1 in 2,700 Beta-Globin Related Hemoglobinopathies: HBB African 1 in 38 99% 1 in 3,700 99% HbC Variant (AR) Caucasian 1 in % 1 in 2,107,000 NM_ Latino 1 in % 1 in 21,500 Variant Tested: c.19g>a, p.e7k Worldwide 1 in % 1 in 41,700 Beta-Globin Related Hemoglobinopathies: HBB African 1 in 11 99% 1 in 1,000 99% HbS Variant (Sickle Cell Disease) (AR) Caucasian 1 in % 1 in 790,000 NM_ Latino 1 in % 1 in 23,100 South Asian 1 in % 1 in 80,900 Variant Tested: c.20a>t, p.e7v Worldwide 1 in % 1 in 11,400 3-Beta-Hydroxysteroid Deficiency (AR) HSD3B2 African 1 in % 1 in 7,000 99% NM_ Ashkenazi Jewish 1 in % 1 in 164,000 East Asian 1 in % 1 in 181,000 Caucasian 1 in % 1 in 3,300 Latino 1 in % 1 in 5,500 South Asian 1 in % 1 in 7,200 Worldwide 1 in % 1 in 4,900 Beta-Ketothiolase Deficiency (AR) ACAT1 African 1 in % 1 in 120,000 99% NM_ East Asian 1 in % 1 in 590 Caucasian 1 in % 1 in 3,500 Latino 1 in % 1 in 3,400 South Asian 1 in % 1 in 2,500 Worldwide 1 in % 1 in 3,100
6 Bilateral Frontoparietal Polymicrogyria (AR) GPR56 African 1 in % 1 in 91,600 99% NM_ (ADGRG1) East Asian 1 in % 1 in 143,000 Finnish 1 in % 1 in 137,000 Caucasian 1 in % 1 in 203,000 Latino 1 in % 1 in 15,300 South Asian 1 in % 1 in 64,000 Worldwide 1 in % 1 in 61,500 Biotinidase Deficiency (AR) BTD African 1 in 52 93% 1 in % NM_ Ashkenazi Jewish 1 in 15 99% 1 in 1,400 East Asian 1 in % 1 in 3,800 Finnish 1 in 9 99% 1 in 810 Caucasian 1 in 12 98% 1 in 500 Latino 1 in 24 97% 1 in 740 South Asian 1 in 7 98% 1 in 370 Worldwide 1 in 13 98% 1 in 550 Bloom Syndrome (AR) BLM African 1 in % 1 in 53,100 99% NM_ Ashkenazi Jewish 1 in % 1 in 11,700 East Asian 1 in % 1 in 33,600 Finnish 1 in % 1 in 71,100 Caucasian 1 in % 1 in 7,400 Latino 1 in % 1 in 49,400 South Asian 1 in % 1 in 12,500 Worldwide 1 in % 1 in 11,800 Canavan Disease (AR) ASPA African 1 in % 1 in 37,000 98% NM_ Ashkenazi Jewish 1 in 50 98% 1 in 2,400 Finnish 1 in % 1 in 12,000 Caucasian 1 in % 1 in 4,000 Latino 1 in % 1 in 7,100 South Asian 1 in % 1 in 5,000 Worldwide 1 in % 1 in 5,200 Carbamoylphosphate Synthetase I CPS1 African 1 in % 1 in % Deficiency (AR) Ashkenazi Jewish 1 in % 1 in 82,000 NM_ East Asian 1 in % 1 in 610 Finnish 1 in % 1 in 3,900 Caucasian 1 in % 1 in 990 Latino 1 in % 1 in 1,800 South Asian 1 in % 1 in 1,900 Worldwide 1 in % 1 in 1,200 Carnitine Palmitoyltransferase IA CPT1A African 1 in % 1 in 255,000 99% Deficiency (AR) Ashkenazi Jewish 1 in % 1 in 49,000 NM_ East Asian 1 in % 1 in 143,000 Finnish 1 in % 1 in 7,900 Caucasian 1 in % 1 in 23,800 Latino 1 in % 1 in 5,500 South Asian 1 in % 1 in 7,500 Worldwide 1 in % 1 in 7,200 Hutterite 1 in 16 99% 1 in 1,500 Carnitine Palmitoyltransferase II CPT2 African 1 in % 1 in 1,300 99% Deficiency (AR) Ashkenazi Jewish 1 in 41 99% 1 in 4,000 NM_ East Asian 1 in % 1 in 930 Finnish 1 in % 1 in 24,700 Caucasian 1 in % 1 in 670 Latino 1 in % 1 in 3,700 South Asian 1 in % 1 in 11,900 Worldwide 1 in % 1 in 1,100
7 Carpenter Syndrome (AR) RAB23 African 1 in % 1 in 19,700 98% NM_ Finnish 1 in % 1 in 215,000 Caucasian 1 in % 1 in 21,100 Worldwide 1 in % 1 in 28,100 Cartilage-Hair Hypoplasia (AR) RMRP African 1 in % 1 in % NR_ Ashkenazi Jewish 1 in 68 99% 1 in 6,700 East Asian 1 in % 1 in 440 Finnish 1 in 49 99% 1 in 4,800 Caucasian 1 in % 1 in 960 Latino 1 in % 1 in 2,500 South Asian 1 in % 1 in 1,200 Worldwide 1 in % 1 in 950 Cerebral Creatine Deficiency Syndrome 1 (XL) SLC6A8 Worldwide < 1 in 50,000 76% 1 in 210,000 96% NM_ Exception: Exons 3, 4 Cerebral Creatine Deficiency Syndrome 2 (AR) GAMT African 1 in % 1 in 27,200 98% NM_ Ashkenazi Jewish 1 in % 1 in 70,200 East Asian 1 in % 1 in 57,500 Caucasian 1 in % 1 in 6,500 Latino 1 in % 1 in 15,800 South Asian 1 in % 1 in 130,000 Worldwide 1 in % 1 in 11,400 Portuguese 1 in % 1 in 6,200 Cerebrotendinous Xanthomatosis (AR) CYP27A1 African 1 in % 1 in 6,100 99% NM_ Ashkenazi Jewish 1 in % 1 in 33,000 East Asian 1 in % 1 in 750 Finnish 1 in % 1 in 111,000 Caucasian 1 in % 1 in 3,900 Latino 1 in % 1 in 3,800 South Asian 1 in % 1 in 960 Worldwide 1 in % 1 in 2,600 Sephardic Jewish - Moroccan 1 in 76 99% 1 in 2,500 Charcot-Marie-Tooth Disease, Type 4D (AR) NDRG1 East Asian 1 in % 1 in 225,000 99% NM_ Caucasian 1 in % 1 in 730,000 South Asian 1 in % 1 in 479,000 Worldwide 1 in % 1 in 693,000 Roma 1 in 22 99% 1 in 2,100 Charcot-Marie-Tooth Disease, Type 5 / PRPS1 Worldwide < 1 in 50,000 56% 1 in 115,000 99% Arts Syndrome (XL) NM_ Charcot-Marie-Tooth Disease, X-Linked (XL) GJB1 Worldwide 1 in % 1 in 6,800 99% NM_ Choreoacanthocytosis (AR) VPS13A African 1 in % 1 in 3,100 98% NM_ Ashkenazi Jewish 1 in % 1 in 31,300 East Asian 1 in % 1 in 4,700 Finnish 1 in % 1 in 30,700 Caucasian 1 in % 1 in 13,100 Latino 1 in % 1 in 2,500 South Asian 1 in % 1 in 9,900 Worldwide 1 in % 1 in 6,700 Choroideremia (XL) CHM Worldwide 1 in 10,000 92% 1 in 125,000 99% NM_
8 Chronic Granulomatous Disease CYBA African 1 in % 1 in 3,600 96% (CYBA-Related) (AR) Finnish 1 in % 1 in 15,900 NM_ Caucasian 1 in % 1 in 5,000 Latino 1 in % 1 in 48,300 South Asian 1 in % 1 in 4,800 Worldwide 1 in % 1 in 3,700 Sephardic Jewish - Moroccan 1 in 13 83% 1 in 72 Chronic Granulomatous Disease CYBB Worldwide < 1 in 50,000 83% 1 in 290,000 98% (CYBB-Related) (XL) NM_ Citrin Deficiency (AR) SLC25A13 African 1 in % 1 in 1,700 99% NM_ Ashkenazi Jewish 1 in % 1 in 27,300 East Asian 1 in 48 98% 1 in 2,300 Caucasian 1 in % 1 in 11,700 Latino 1 in % 1 in 14,500 South Asian 1 in % 1 in 3,600 Worldwide 1 in % 1 in 4,700 Citrullinemia, Type I (AR) ASS1 African 1 in % 1 in 2,600 99% NM_ Ashkenazi Jewish 1 in % 1 in 167,000 East Asian 1 in % 1 in 80,800 Finnish 1 in % 1 in 298,000 Caucasian 1 in % 1 in 2,500 Latino 1 in % 1 in 6,600 South Asian 1 in % 1 in 1,300 Worldwide 1 in % 1 in 2,700 Cohen Syndrome (AR) VPS13B African 1 in % 1 in 4,500 98% NM_ Ashkenazi Jewish 1 in % 1 in 3,700 East Asian 1 in % 1 in 12,700 Finnish 1 in % 1 in 6,000 Caucasian 1 in % 1 in 6,400 Latino 1 in % 1 in 21,500 South Asian 1 in % 1 in 15,600 Worldwide 1 in % 1 in 7,000 Combined Malonic and Methylmalonic ACSF3 African 1 in % 1 in 12,500 99% Aciduria (AR) Ashkenazi Jewish 1 in 59 99% 1 in 5,800 NM_ East Asian 1 in % 1 in 23,400 Finnish 1 in % 1 in 34,500 Caucasian 1 in 71 97% 1 in 2,400 Latino 1 in % 1 in 19,300 South Asian 1 in % 1 in 340 Worldwide 1 in 99 94% 1 in 1,700 Combined Oxidative Phosphorylation GFM1 African 1 in % 1 in 51,400 99% Deficiency 1 (AR) East Asian 1 in % 1 in 8,100 NM_ Finnish 1 in % 1 in 84,000 Caucasian 1 in % 1 in 13,500 Latino 1 in % 1 in 132,000 South Asian 1 in % 1 in 76,800 Worldwide 1 in % 1 in 20,200 Combined Oxidative Phosphorylation TSFM African 1 in % 1 in 68,000 99% Deficiency 3 (AR) Finnish 1 in 35 99% 1 in 3,400 NM_ Caucasian 1 in % 1 in 27,000 Latino 1 in % 1 in 180,000 Worldwide 1 in % 1 in 21,200
9 Combined Pituitary Hormone PROP1 Finnish 1 in % 1 in 111,000 99% Deficiency 2 (AR) Caucasian 1 in % 1 in 2,800 NM_ Latino 1 in % 1 in 7,400 Worldwide 1 in % 1 in 5,300 Combined Pituitary Hormone LHX3 East Asian 1 in % 1 in 121,000 99% Deficiency 3 (AR) Caucasian 1 in % 1 in 140,000 NM_ Worldwide 1 in % 1 in 197,000 Combined SAP Deficiency (AR) PSAP African 1 in % 1 in 194,000 99% NM_ Caucasian 1 in % 1 in 44,100 Latino 1 in % 1 in 88,300 Worldwide 1 in % 1 in 77,800 Congenital Adrenal Hyperplasia due to CYP17A1 African 1 in % 1 in 5,200 99% 17-Alpha-Hydroxylase Deficiency (AR) East Asian 1 in % 1 in 840 NM_ Finnish 1 in % 1 in 3,700 Caucasian 1 in % 1 in 1,800 Latino 1 in % 1 in 8,100 South Asian 1 in % 1 in 6,000 Worldwide 1 in % 1 in 2,400 Classic Congenital Adrenal Hyperplasia CYP21A2 Ashkenazi Jewish 1 in 40 95% 1 in % due to 21-Hydroxylase Deficiency (AR) Caucasian 1 in 67 95% 1 in 1,300 NM_ Worldwide 1 in 60 95% 1 in 1,200 Non-Classic Congenital Adrenal Hyperplasia CYP21A2 Ashkenazi Jewish 1 in 7 95% 1 in % due to 21-Hydroxylase Deficiency (AR) Caucasian 1 in 11 95% 1 in 200 NM_ Worldwide 1 in 16 95% 1 in 300 Congenital Amegakaryocytic MPL African 1 in % 1 in 5,400 99% Thrombocytopenia (AR) Ashkenazi Jewish 1 in 60 99% 1 in 5,900 NM_ East Asian 1 in % 1 in 68,000 Finnish 1 in % 1 in 180,000 Caucasian 1 in % 1 in 3,100 Latino 1 in % 1 in 4,000 South Asian 1 in % 1 in 61,600 Worldwide 1 in % 1 in 4,700 Congenital Disorder of Glycosylation, PMM2 African 1 in % 1 in 24,400 99% Type Ia (AR) Ashkenazi Jewish 1 in 66 99% 1 in 6,500 NM_ East Asian 1 in % 1 in 550 Finnish 1 in 58 99% 1 in 5,700 Caucasian 1 in 58 89% 1 in 540 Latino 1 in % 1 in 1,200 South Asian 1 in % 1 in 2,000 Worldwide 1 in 80 91% 1 in 840 Congenital Disorder of Glycosylation, MPI African 1 in % 1 in 2,000 99% Type Ib (AR) East Asian 1 in % 1 in 2,100 NM_ Finnish 1 in % 1 in 6,200 Caucasian 1 in % 1 in 5,600 Latino 1 in % 1 in 15,100 South Asian 1 in % 1 in 7,500 Worldwide 1 in % 1 in 4,900
10 Congenital Disorder of Glycosylation, ALG6 African 1 in % 1 in 3,700 99% Type Ic (AR) Ashkenazi Jewish 1 in % 1 in 5,000 NM_ East Asian 1 in % 1 in 2,300 Finnish 1 in % 1 in 198,000 Caucasian 1 in % 1 in 4,100 Latino 1 in % 1 in 5,600 South Asian 1 in % 1 in 1,900 Worldwide 1 in % 1 in 3,500 Congenital Insensitivity to Pain with NTRK1 African 1 in % 1 in 4,100 99% Anhidrosis (AR) East Asian 1 in % 1 in 1,100 NM_ Finnish 1 in % 1 in 2,000 Caucasian 1 in % 1 in 5,700 Latino 1 in % 1 in 15,700 South Asian 1 in % 1 in 14,900 Worldwide 1 in % 1 in 3,600 Sephardic Jewish - Moroccan N/A 99% N/A Congenital Myasthenic Syndrome CHRNE African 1 in % 1 in 29,900 99% (CHRNE-Related) (AR) Ashkenazi Jewish 1 in % 1 in 14,800 NM_ East Asian 1 in % 1 in 29,800 Finnish 1 in % 1 in 9,300 Caucasian 1 in % 1 in 4,100 Latino 1 in % 1 in 4,900 South Asian 1 in % 1 in 2,800 Worldwide 1 in % 1 in 4,680 Southeastern European Roma 1 in 25 99% 1 in 2,400 Congenital Myasthenic Syndrome RAPSN African 1 in % 1 in 5,700 99% (RAPSN-Related) (AR) Ashkenazi Jewish 1 in % 1 in 25,200 NM_ East Asian 1 in % 1 in 47,000 Finnish 1 in % 1 in 98,800 Caucasian 1 in % 1 in 2,900 Latino 1 in % 1 in 3,200 South Asian 1 in % 1 in 12,100 Worldwide 1 in % 1 in 4,400 Sephardic Jewish - N/A 99% N/A Iraqi and Iranian Congenital Neutropenia (HAX1-Related) (AR) HAX1 African 1 in % 1 in 79,900 99% NM_ Ashkenazi Jewish 1 in % 1 in 82,400 East Asian 1 in % 1 in 126,000 Caucasian 1 in % 1 in 82,300 Latino 1 in % 1 in 280,000 South Asian 1 in % 1 in 513,000 Worldwide 1 in % 1 in 107,000 Congenital Neutropenia (VPS45-Related) (AR) VPS45 African 1 in % 1 in 112,000 99% NM_ East Asian 1 in % 1 in 110,000 Finnish 1 in % 1 in 5,500 Caucasian 1 in % 1 in 163,000 Latino 1 in % 1 in 335,000 South Asian 1 in % 1 in 170,000 Worldwide 1 in % 1 in 43,200
11 Corneal Dystrophy and Perceptive SLC4A11 African 1 in % 1 in 1,100 99% Deafness (AR) East Asian 1 in % 1 in 1,800 NM_ Finnish 1 in % 1 in 389,000 Caucasian 1 in % 1 in 4,600 Latino 1 in % 1 in 1,400 South Asian 1 in % 1 in 2,500 Worldwide 1 in % 1 in 2,200 Corticosterone Methyloxidase Deficiency (AR) CYP11B2 African 1 in % 1 in % NM_ East Asian 1 in % 1 in 1,700 Finnish 1 in % 1 in 1,400 Caucasian 1 in % 1 in 1,500 Latino 1 in % 1 in 1,700 South Asian 1 in % 1 in 3,200 Worldwide 1 in % 1 in 1,500 Exception: Exons 3-7 Sephardic Jewish - Iranian 1 in 30 95% 1 in 580 Cystic Fibrosis (AR) CFTR African 1 in 58 91% 1 in % NM_ Ashkenazi Jewish 1 in 24 98% 1 in 1,200 East Asian 1 in % 1 in 1,400 Finnish 1 in 75 93% 1 in 1,100 Caucasian 1 in 23 95% 1 in 440 Latino 1 in 40 96% 1 in 1,000 South Asian 1 in 73 91% 1 in 800 Exception: Exon 10 Worldwide 1 in 33 94% 1 in 500 Cystinosis (AR) CTNS African 1 in % 1 in 2,900 99% NM_ East Asian 1 in % 1 in 7,100 Caucasian 1 in % 1 in 7,700 Latino 1 in % 1 in 15,400 South Asian 1 in % 1 in 4,900 Worldwide 1 in % 1 in 8,200 French Canadian - 1 in 39 90% 1 in 380 Saguenay-Lac St. Jean Sephardic Jewish - Moroccan 1 in % 1 in 1,200 D-Bifunctional Protein Deficiency (AR) HSD17B4 African 1 in % 1 in 2,200 92% NM_ East Asian 1 in % 1 in 2,700 Caucasian 1 in % 1 in 5,000 Latino 1 in % 1 in 5,500 South Asian 1 in % 1 in 8,200 Worldwide 1 in % 1 in 4,900 Deafness, Autosomal Recessive 77 (AR) LOXHD1 African 1 in % 1 in 2,000 99% NM_ Ashkenazi Jewish 1 in % 1 in 12,500 East Asian 1 in % 1 in 2,800 Finnish 1 in % 1 in 50,700 Caucasian 1 in % 1 in 6,700 Latino 1 in % 1 in 9,100 South Asian 1 in % 1 in 35,200 Worldwide 1 in % 1 in 4,000 Duchenne Muscular Dystrophy/ DMD Worldwide 1 in % 1 in 10,000 99% Becker Muscular Dystrophy (XL) NM_
12 Dyskeratosis Congenita (RTEL1-Related) (AR) RTEL1 African 1 in % 1 in 75,500 99% NM_ Ashkenazi Jewish 1 in % 1 in 11,000 East Asian 1 in % 1 in 3,900 Finnish 1 in % 1 in 112,000 Caucasian 1 in % 1 in 9,800 Latino 1 in % 1 in 138,000 South Asian 1 in % 1 in 72,900 Worldwide 1 in % 1 in 12,200 Dystrophic Epidermolysis Bullosa (AR) COL7A1 African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 3,900 East Asian 1 in % 1 in 1,400 Finnish 1 in 33 96% 1 in 780 Caucasian 1 in % 1 in 900 Latino 1 in % 1 in 930 South Asian 1 in 95 90% 1 in 980 Worldwide 1 in 92 90% 1 in 870 Ehlers-Danlos Syndrome, Type VIIC (AR) ADAMTS2 Ashkenazi Jewish 1 in % 1 in 16,300 99% NM_ East Asian 1 in % 1 in 63,000 Caucasian 1 in % 1 in 243,000 Latino 1 in % 1 in 419,000 South Asian 1 in % 1 in 380,000 Exception: Exon 1 Worldwide 1 in % 1 in 142,000 Ellis-van Creveld Syndrome (EVC-Related) (AR) EVC African 1 in % 1 in 18,500 97% NM_ East Asian 1 in % 1 in 15,200 Finnish 1 in % 1 in 30,000 Caucasian 1 in % 1 in 4,200 Latino 1 in % 1 in 39,900 South Asian 1 in % 1 in 9,500 Worldwide 1 in % 1 in 7,300 Exception: Exon 1 Lancaster County Amish 1 in 12 97% 1 in 370 Emery-Dreifuss Myopathy 1 (XL) EMD Worldwide < 1 in 50,000 94% 1 in 833,000 98% NM_ Enhanced S-Cone Syndrome (AR) NR2E3 African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in 81 97% 1 in 3,100 East Asian 1 in % 1 in 550 Caucasian 1 in % 1 in 1,500 Latino 1 in % 1 in 12,000 South Asian 1 in % 1 in 2,100 Worldwide 1 in % 1 in 1,600 Ethylmalonic Encephalopathy (AR) ETHE1 African 1 in % 1 in 94,800 98% NM_ Caucasian 1 in % 1 in 3,400 Latino 1 in % 1 in 12,500 South Asian 1 in % 1 in 192,000 Worldwide 1 in % 1 in 6,600 Fabry Disease (XL) GLA Worldwide 1 in % 1 in % NM_ Factor IX Deficiency (XL) F9 Worldwide 1 in % 1 in % NM_
13 Factor XI Deficiency (AR) F11 African 1 in % 1 in 1,800 99% NM_ Ashkenazi Jewish 1 in 12 99% 1 in 730 East Asian 1 in 94 79% 1 in 440 Finnish 1 in % 1 in 9,100 Caucasian 1 in % 1 in 1,600 Latino 1 in % 1 in 1,200 South Asian 1 in % 1 in 1,200 Worldwide 1 in % 1 in 1,200 Familial Dysautonomia (AR) IKBKAP African 1 in % 1 in 40,800 99% NM_ Ashkenazi Jewish 1 in 35 99% 1 in 3,400 East Asian 1 in % 1 in 78,300 Finnish 1 in % 1 in 70,600 Caucasian 1 in % 1 in 50,500 Latino 1 in % 1 in 80,000 South Asian 1 in % 1 in 85,400 Worldwide 1 in % 1 in 34,400 Familial Hypercholesterolemia (AR) LDLR African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 4,000 East Asian 1 in 66 75% 1 in 260 Finnish 1 in % 1 in 790 Caucasian 1 in % 1 in 280 Latino 1 in % 1 in 370 South Asian 1 in % 1 in 270 Worldwide 1 in % 1 in 310 French Canadian 1 in % 1 in % South African Afrikaner 1 in 70 94% 1 in 1,200 Familial Hypercholesterolemia, LDLRAP1 African 1 in % 1 in 144,000 98% Autosomal Recessive (AR) Caucasian 1 in % 1 in 136,000 NM_ Latino 1 in % 1 in 140,000 South Asian 1 in % 1 in 192,000 Worldwide 1 in % 1 in 171,000 Sardinian 1 in % 1 in 7,100 Familial Hyperinsulinism (ABCC8-Related) ABCC8 African 1 in % 1 in % (AR) Ashkenazi Jewish 1 in 62 88% 1 in 510 NM_ East Asian 1 in % 1 in 240 Finnish 1 in % 1 in 2,600 Caucasian 1 in % 1 in 420 Latino 1 in % 1 in 1,400 South Asian 1 in % 1 in 840 Worldwide 1 in % 1 in 460 Familial Hyperinsulinism (KCNJ11-Related) KCNJ11 African 1 in % 1 in 290,000 99% (AR) Caucasian 1 in % 1 in 3,500 NM_ Latino 1 in % 1 in 1,700 South Asian 1 in % 1 in 5,000 Worldwide 1 in % 1 in 2,600
14 Familial Mediterranean Fever (AR) MEFV African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in 8 99% 1 in 720 East Asian 1 in % 1 in 3,400 Finnish 1 in 29 99% 1 in 2,800 Caucasian 1 in 40 97% 1 in 1,200 Latino 1 in 74 95% 1 in 1,500 South Asian 1 in 56 95% 1 in 1,000 Worldwide 1 in 40 97% 1 in 1,200 Sepharic Jewish 1 in 14 99% 1 in 1,300 Armenian 1 in 5 99% 1 in 400 Turkish 1 in 5 75% 1 in 17 Fanconi Anemia, Group A (AR) FANCA African 1 in % 1 in 1,100 95% NM_ Ashkenazi Jewish 1 in % 1 in 2,500 East Asian 1 in % 1 in 1,700 Finnish 1 in % 1 in 5,300 Caucasian 1 in % 1 in 1,100 Latino 1 in % 1 in 2,200 South Asian 1 in % 1 in 1,100 Worldwide 1 in % 1 in 1,300 Spanish Roma 1 in 64 95% 1 in 1,300 Sephardic Jewish - 1 in % 1 in 940 Moroccan and Tunisian Fanconi Anemia, Group C (AR) FANCC African 1 in % 1 in 3,700 99% NM_ Ashkenazi Jewish 1 in 82 99% 1 in 8,100 East Asian 1 in % 1 in 34,300 Finnish 1 in % 1 in 119,000 Caucasian 1 in % 1 in 11,600 Latino 1 in % 1 in 112,000 South Asian 1 in % 1 in 102,000 Worldwide 1 in % 1 in 13,700 Fanconi Anemia, Group G (AR) FANCG African 1 in % 1 in 49,300 99% NM_ East Asian 1 in % 1 in 1,200 Finnish 1 in % 1 in 122,000 Caucasian 1 in % 1 in 28,100 Latino 1 in % 1 in 186,000 South Asian 1 in % 1 in 128,000 Worldwide 1 in % 1 in 12,300 Fragile X Syndrome (XL) FMR1 African 1 in % 1 in 26,700 99% NM_ Ashkenazi Jewish 1 in 84 99% 1 in 8,300 East Asian 1 in % 1 in 222,000 Caucasian 1 in % 1 in 18,600 Latino 1 in % 1 in 20,500 South Asian 1 in % 1 in 17,100 Worldwide 1 in % 1 in 18,000 Fumarase Deficiency (AR) FH African 1 in % 1 in 6,100 98% NM_ Ashkenazi Jewish 1 in 99 98% 1 in 4,900 Finnish 1 in % 1 in 9,400 Caucasian 1 in % 1 in 3,700 Latino 1 in % 1 in 40,000 South Asian 1 in % 1 in 5,100 Worldwide 1 in % 1 in 5,300
15 Galactokinase Deficiency (AR) GALK1 African 1 in % 1 in % NM_ East Asian 1 in % 1 in 1,600 Finnish 1 in % 1 in 129,000 Caucasian 1 in % 1 in 2,700 Latino 1 in % 1 in 3,000 South Asian 1 in % 1 in 2,700 Worldwide 1 in % 1 in 2,300 Roma 1 in 47 98% 1 in 2,300 Galactosemia (AR) GALT African 1 in 87 86% 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 4,100 East Asian 1 in % 1 in 350 Finnish 1 in % 1 in 12,600 Caucasian 1 in % 1 in 1,600 Latino 1 in % 1 in 3,000 South Asian 1 in % 1 in 1,800 Worldwide 1 in % 1 in 1,000 Irish Travellers 1 in 11 99% 1 in 1,000 Gaucher Disease (AR) GBA Caucasian 1 in % 1 in 1,300 95% NM_ Ashkenazi Jewish 1 in 15 95% 1 in 280 Worldwide 1 in % 1 in 1,100 Gitelman Syndrome (AR) SLC12A3 African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 6,000 East Asian 1 in 28 88% 1 in 230 Finnish 1 in % 1 in 450 Caucasian 1 in 73 75% 1 in 290 Latino 1 in % 1 in 730 South Asian 1 in % 1 in 460 Worldwide 1 in 82 78% 1 in 370 Glutaric Acidemia, Type I (AR) GCDH African 1 in 93 76% 1 in % NM_ East Asian 1 in % 1 in 3,600 Finnish 1 in % 1 in 3,700 Caucasian 1 in % 1 in 1,900 Latino 1 in % 1 in 3,700 South Asian 1 in % 1 in 390 Worldwide 1 in % 1 in 1,000 Oji-Cree First Nations (N. Manitoba) 1 in 8 99% 1 in 700 Old Order Amish of Pennsylvania 1 in 11 99% 1 in 1,000 Lumbee Native American 1 in 16 99% 1 in 1,500 Glutaric Acidemia, Type IIa (AR) ETFA African 1 in % 1 in 6,300 97% NM_ East Asian 1 in % 1 in 2,100 Caucasian 1 in % 1 in 4,700 Latino 1 in % 1 in 15,000 South Asian 1 in % 1 in 36,600 Worldwide 1 in % 1 in 6,400 Glutaric Acidemia, Type IIc (AR) ETFDH African 1 in % 1 in 1,000 99% NM_ Ashkenazi Jewish 1 in % 1 in 123,000 East Asian 1 in 89 66% 1 in 260 Finnish 1 in % 1 in 5,700 Caucasian 1 in % 1 in 1,700 Latino 1 in % 1 in 1,400 South Asian 1 in % 1 in 1,400 Worldwide 1 in % 1 in 1,200
16 Glycine Encephalopathy (AMT-Related) (AR) AMT East Asian 1 in % 1 in 2,100 99% NM_ Finnish 1 in % 1 in 10,700 Caucasian 1 in % 1 in 2,300 Latino 1 in % 1 in 690 South Asian 1 in % 1 in 90,400 Worldwide 1 in % 1 in 2,300 Glycine Encephalopathy (GLDC-Related) (AR) GLDC African 1 in % 1 in 1,000 95% NM_ East Asian 1 in % 1 in 330 Finnish 1 in % 1 in 740 Caucasian 1 in % 1 in 840 Latino 1 in % 1 in 900 South Asian 1 in % 1 in 1,300 Exception: Exon 1 Worldwide 1 in % 1 in 780 Glycogen Storage Disease, Type Ia (AR) G6PC African 1 in % 1 in 7,000 99% NM_ Ashkenazi Jewish 1 in 75 99% 1 in 7,400 East Asian 1 in % 1 in 410 Finnish 1 in % 1 in 54,800 Caucasian 1 in % 1 in 5,300 Latino 1 in % 1 in 3,100 South Asian 1 in % 1 in 15,100 Worldwide 1 in % 1 in 3,200 Glycogen Storage Disease, Type Ib (AR) SLC37A4 African 1 in % 1 in 141,000 99% NM_ Ashkenazi Jewish 1 in % 1 in 125,000 East Asian 1 in % 1 in 3,900 Finnish 1 in % 1 in 78,700 Caucasian 1 in % 1 in 7,300 Latino 1 in % 1 in 11,700 South Asian 1 in % 1 in 13,000 Worldwide 1 in % 1 in 9,600 Glycogen Storage Disease, Type II (AR) GAA African 1 in 71 82% 1 in % NM_ Ashkenazi Jewish 1 in 76 97% 1 in 3,000 East Asian 1 in 63 78% 1 in 280 Finnish 1 in % 1 in 890 Caucasian 1 in 49 91% 1 in 520 Latino 1 in 95 86% 1 in 690 South Asian 1 in % 1 in 1,500 Worldwide 1 in 71 87% 1 in 530 Glycogen Storage Disease, Type III (AR) AGL African 1 in % 1 in 1,300 99% NM_ East Asian 1 in % 1 in 54,800 Finnish 1 in % 1 in 158,000 Caucasian 1 in % 1 in 5,700 Latino 1 in % 1 in 12,700 South Asian 1 in % 1 in 1,900 Worldwide 1 in % 1 in 3,700 Sephardic Jewish - Moroccan 1 in 34 99% 1 in 3,300 Faroese 1 in 28 99% 1 in 2,700 Glycogen Storage Disease, Type IV / GBE1 African 1 in % 1 in 2,600 98% Adult Polyglucosan Body Disease (AR) Ashkenazi Jewish 1 in 55 98% 1 in 2,700 NM_ East Asian 1 in % 1 in 64,000 Finnish 1 in % 1 in 7,700 Caucasian 1 in % 1 in 2,400 Latino 1 in % 1 in 4,500 South Asian 1 in % 1 in 2,600 Worldwide 1 in % 1 in 3,000
17 Glycogen Storage Disease, Type V (AR) PYGM African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 420 East Asian 1 in % 1 in 1,400 Finnish 1 in % 1 in 3,400 Caucasian 1 in % 1 in 1,200 Latino 1 in % 1 in 1,800 South Asian 1 in % 1 in 2,700 Worldwide 1 in % 1 in 1,300 Sephardic Jewish - Kurdish 1 in 84 98% 1 in 4,200 Glycogen Storage Disease, Type VII (AR) PFKM African 1 in % 1 in 10,600 99% NM_ Ashkenazi Jewish 1 in % 1 in 9,900 East Asian 1 in % 1 in 7,900 Finnish 1 in % 1 in 3,200 Caucasian 1 in % 1 in 4,300 South Asian 1 in % 1 in 308,000 Worldwide 1 in % 1 in 6,300 GRACILE Syndrome and Other BCS1L- BCS1L African 1 in % 1 in 2,100 99% Related Disorders (AR) Ashkenazi Jewish 1 in % 1 in 16,800 NM_ East Asian 1 in % 1 in 82,100 Finnish 1 in 95 93% 1 in 1,400 Caucasian 1 in % 1 in 3,900 Latino 1 in % 1 in 55,100 South Asian 1 in % 1 in 4,800 Worldwide 1 in % 1 in 3,900 Hemochromatosis, Type 2A (AR) HFE2 African 1 in % 1 in 2,400 99% NM_ East Asian 1 in % 1 in 740 Caucasian 1 in % 1 in 7,000 Latino 1 in % 1 in 3,300 South Asian 1 in % 1 in 4,800 Worldwide 1 in % 1 in 4,000 Hemochromatosis, Type 3 (AR) TFR2 African 1 in % 1 in 4,200 99% NM_ East Asian 1 in % 1 in 275,000 Caucasian 1 in % 1 in 11,400 Latino 1 in % 1 in 37,700 South Asian 1 in % 1 in 5,000 Worldwide 1 in % 1 in 7,400 Hereditary Fructose Intolerance (AR) ALDOB African 1 in % 1 in 15,900 98% NM_ Ashkenazi Jewish 1 in % 1 in 7,000 East Asian 1 in % 1 in 35,200 Finnish 1 in % 1 in 5,000 Caucasian 1 in 81 96% 1 in 1,900 Latino 1 in % 1 in 3,900 South Asian 1 in % 1 in 8,700 Worldwide 1 in % 1 in 3,000 Hereditary Spastic Paraparesis 49 (AR) TECPR2 African 1 in % 1 in 187,000 99% NM_ Ashkenazi Jewish 1 in % 1 in 15,000 East Asian 1 in % 1 in 166,000 Finnish 1 in % 1 in 92,800 Caucasian 1 in % 1 in 12,400 Latino 1 in % 1 in 559,000 South Asian 1 in % 1 in 2,600 Worldwide 1 in % 1 in 11,100 Sephardic Jewish - Bukharian 1 in 27 99% 1 in 2,600
18 Hermansky-Pudlak Syndrome, Type 1 (AR) HPS1 African 1 in % 1 in 5,680 99% NM_ East Asian 1 in % 1 in 286,000 Finnish 1 in % 1 in 54,900 Caucasian 1 in % 1 in 3,500 Latino 1 in % 1 in 99,800 South Asian 1 in % 1 in 154,000 Worldwide 1 in % 1 in 6,300 Puerto Rican 1 in 59 99% 1 in 5,800 Hermansky-Pudlak Syndrome, Type 3 (AR) HPS3 African 1 in % 1 in 79,800 99% NM_ Ashkenazi Jewish 1 in % 1 in 26,500 East Asian 1 in % 1 in 21,800 Caucasian 1 in % 1 in 49,000 Latino 1 in % 1 in 67,300 95% South Asian 1 in % 1 in 1,850 Worldwide 1 in % 1 in 11,900 HMG-CoA Lyase Deficiency (AR) HMGCL African 1 in % 1 in 48,100 98% NM_ East Asian 1 in % 1 in 113,000 Finnish 1 in % 1 in 66,500 Caucasian 1 in % 1 in 2,700 Latino 1 in % 1 in 56,100 South Asian 1 in % 1 in 64,100 Worldwide 1 in % 1 in 5,400 Holocarboxylase Synthetase Deficiency (AR) HLCS African 1 in % 1 in 6,800 99% NM_ East Asian 1 in % 1 in 6,900 Finnish 1 in % 1 in 143,000 Caucasian 1 in % 1 in 5,500 Latino 1 in % 1 in 5,200 South Asian 1 in % 1 in 110,000 Worldwide 1 in % 1 in 7,400 Homocystinuria (CBS-Related) (AR) CBS African 1 in % 1 in 3,500 97% NM_ Ashkenazi Jewish 1 in % 1 in 3,500 East Asian 1 in % 1 in 2,200 Finnish 1 in % 1 in 5,600 Caucasian 1 in % 1 in 1,400 Latino 1 in % 1 in 3,100 South Asian 1 in % 1 in 5,000 Worldwide 1 in % 1 in 1,900 Qatari 1 in 21 86% 1 in 140 Homocystinuria due to MTHFR Deficiency (AR) MTHFR Sephardic Jewish - Bukharian 1 in 39 99% 1 in 3,800 99% NM_ Variant tested: p.g158g (Genotyping only) Homocystinuria, cble Type (AR) MTRR African 1 in % 1 in 75,800 99% NM_ Ashkenazi Jewish 1 in % 1 in 166,000 Finnish 1 in % 1 in 152,000 Caucasian 1 in % 1 in 9,600 Latino 1 in % 1 in 12,600 South Asian 1 in % 1 in 256,000 Worldwide 1 in % 1 in 16,100
19 Hydrolethalus Syndrome (AR) HYLS1 African 1 in % 1 in 109,000 99% NM_ East Asian 1 in % 1 in 296,000 Finnish 1 in 51 99% 1 in 5,000 Caucasian 1 in % 1 in 52,100 Latino 1 in % 1 in 88,400 South Asian 1 in % 1 in 220,000 Worldwide 1 in % 1 in 31,600 Hyperornithinemia-Hyperammonemia- SLC25A15 East Asian 1 in % 1 in 30,200 99% Homocitrullinuria Syndrome (AR Finnish 1 in % 1 in 322,000 NM_ Caucasian 1 in % 1 in 5,700 Latino 1 in % 1 in 112,000 South Asian 1 in % 1 in 7,500 Worldwide 1 in % 1 in 8,900 Metis - Saskatchewan 1 in 19 99% 1 in 1,800 Hypohidrotic Ectodermal Dysplasia 1 (XL) EDA Worldwide 1 in % 1 in 22,000 97% NM_ Hypophosphatasia (AR) ALPL African 1 in % 1 in 4,400 99% NM_ Ashkenazi Jewish 1 in % 1 in 2,500 East Asian 1 in % 1 in 5,200 Finnish 1 in 28 96% 1 in 660 Caucasian 1 in % 1 in 790 Latino 1 in % 1 in 880 South Asian 1 in % 1 in 2,500 Worldwide 1 in % 1 in 1,000 Mennonite 1 in 25 99% 1 in 2,400 Inclusion Body Myopathy 2 (AR) GNE African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 4,800 East Asian 1 in % 1 in 2,600 Finnish 1 in % 1 in 5,500 Caucasian 1 in % 1 in 2,000 Latino 1 in % 1 in 2,100 South Asian 1 in 36 98% 1 in 1,600 Worldwide 1 in % 1 in 1,500 Sephardic Jewish - Iranian and Syrian 1 in 10 99% 1 in 900 Infantile Cerebral and Cerebellar Atrophy (AR) MED17 African 1 in % 1 in 75,100 99% NM_ Caucasian 1 in % 1 in 129,000 Latino 1 in % 1 in 559,000 South Asian 1 in % 1 in 308,000 Worldwide 1 in % 1 in 130,000 Sephardic Jewish - Bukharian 1 in 20 99% 1 in 1,900 and Kurdish Isovaleric Acidemia (AR) IVD African 1 in % 1 in 2,400 99% NM_ East Asian 1 in % 1 in 4,200 Finnish 1 in % 1 in 10,700 Caucasian 1 in % 1 in 2,000 Latino 1 in % 1 in 5,100 South Asian 1 in % 1 in 3,000 Worldwide 1 in % 1 in 2,800 Joubert Syndrome 2 (AR) TMEM216 African 1 in % 1 in 336,000 99% NM_ Ashkenazi Jewish 1 in % 1 in 13,600 Caucasian 1 in % 1 in 152,000 Latino 1 in % 1 in 203,000 South Asian 1 in % 1 in 353,000 Worldwide 1 in % 1 in 133,000
20 Joubert Syndrome 7 / Meckel Syndrome 5 / RPGRIP1L African 1 in % 1 in 25,600 99% COACH Syndrome (AR) East Asian 1 in % 1 in 1,100 NM_ Finnish 1 in % 1 in 98,800 Caucasian 1 in % 1 in 31,800 Latino 1 in % 1 in 13,200 South Asian 1 in % 1 in 6,800 Exception: Exon 22 Worldwide 1 in % 1 in 9,000 Junctional Epidermolysis Bullosa LAMA3 African 1 in % 1 in 78,100 99% (LAMA3-Related) (AR) East Asian 1 in % 1 in 49,400 NM_ Finnish 1 in % 1 in 1,200 Caucasian 1 in % 1 in 20,900 Latino 1 in % 1 in 142,000 South Asian 1 in % 1 in 80,900 Worldwide 1 in % 1 in 9,300 Junctional Epidermolysis Bullosa LAMB3 African 1 in % 1 in 8,300 99% (LAMB3-Related) (AR) Ashkenazi Jewish 1 in % 1 in 98,300 NM_ East Asian 1 in % 1 in 8,600 Finnish 1 in % 1 in 95,600 Caucasian 1 in % 1 in 1,900 Latino 1 in % 1 in 112,000 South Asian 1 in % 1 in 62,800 Worldwide 1 in % 1 in 3,800 Junctional Epidermolysis Bullosa LAMC2 African 1 in % 1 in 82,200 99% (LAMC2-Related) (AR) East Asian 1 in % 1 in 28,400 NM_ Caucasian 1 in % 1 in 77,100 Latino 1 in % 1 in 420,000 South Asian 1 in % 1 in 171,000 Worldwide 1 in % 1 in 77,600 Krabbe Disease (AR) GALC African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 1,300 East Asian 1 in 40 81% 1 in 200 Finnish 1 in % 1 in 14,500 Caucasian 1 in 67 88% 1 in 570 Latino 1 in % 1 in 900 South Asian 1 in 35 91% 1 in 370 Worldwide 1 in 74 83% 1 in 440 Druze Northern Israel 1 in 6 99% 1 in 500 Muslim Arab (Jerusalem) 1 in 6 99% 1 in 500 Lamellar Ichthyosis, Type 1 (AR) TGM1 African 1 in % 1 in % NM_ Ashkenazi Jewish 1 in % 1 in 61,900 East Asian 1 in % 1 in 6,600 Finnish 1 in % 1 in 2,300 Caucasian 1 in % 1 in 1,100 Latino 1 in % 1 in 4,000 South Asian 1 in 79 15% 1 in 93 Worldwide 1 in % 1 in 540 Norwegian 1 in % 1 in 750 Leber Congenital Amaurosis 10 and Other CEP290 African 1 in % 1 in 1,300 99% CEP290-Related Ciliopathies (AR) Ashkenazi Jewish 1 in % 1 in 3,200 NM_ East Asian 1 in 32 97% 1 in 1,100 Finnish 1 in % 1 in 71,200 Caucasian 1 in 97 96% 1 in 2,700 Latino 1 in % 1 in 2,000 South Asian 1 in % 1 in 22,100 Exception: Exons 13, 32, 40 Worldwide 1 in % 1 in 2,800
21 Leber Congenital Amaurosis 13 (AR) RDH12 African 1 in % 1 in 4,100 99% NM_ East Asian 1 in % 1 in 87,600 Caucasian 1 in % 1 in 5,500 Latino 1 in % 1 in 2,600 South Asian 1 in % 1 in 1,000 Worldwide 1 in % 1 in 2,800 Leber Congenital Amaurosis 2 / RPE65 African 1 in % 1 in 5,400 99% Retinitis Pigmentosa 20 (AR) East Asian 1 in % 1 in 2,100 NM_ Finnish 1 in % 1 in 4,100 Caucasian 1 in % 1 in 2,500 Latino 1 in % 1 in 1,400 South Asian 1 in % 1 in 490 Worldwide 1 in % 1 in 1,700 Sephardic Jewish - 1 in 90 99% 1 in 8,900 North African Leber Congenital Amaurosis 5 (AR) LCA5 Ashkenazi Jewish 1 in % 1 in 23,300 99% NM_ East Asian 1 in % 1 in 4,200 Caucasian 1 in % 1 in 14,200 Latino 1 in % 1 in 4,200 South Asian 1 in % 1 in 3,800 Worldwide 1 in % 1 in 8,800 Leber Congenital Amaurosis 8 / CRB1 African 1 in % 1 in 3,300 99% Retinitis Pigmentosa 12 (AR) Ashkenazi Jewish 1 in % 1 in 4,400 NM_ East Asian 1 in % 1 in 960 Finnish 1 in % 1 in 11,500 Caucasian 1 in % 1 in 990 Latino 1 in % 1 in 2,000 South Asian 1 in % 1 in 1,000 Worldwide 1 in % 1 in 1,300 Leigh Syndrome, French-Canadian LRPPRC African 1 in % 1 in 65,400 99% Type (AR) East Asian 1 in % 1 in 22,100 NM_ Finnish 1 in % 1 in 47,100 Caucasian 1 in % 1 in 32,400 Latino 1 in % 1 in 178,000 South Asian 1 in % 1 in 75,700 Worldwide 1 in % 1 in 13,500 French Canadian - Saguenay- 1 in 23 99% 1 in 2,200 Lac St. Jean Lethal Congenital Contracture Syndrome 1 / GLE1 African 1 in % 1 in 3,300 99% Cell Lethal Arthrogryposis with Anterior East Asian 1 in % 1 in 3,100 Horn Disease (AR) Finnish 1 in 40 97% 1 in 1,500 NM_ Caucasian 1 in % 1 in 4,800 Latino 1 in % 1 in 2,800 South Asian 1 in % 1 in 4,800 Worldwide 1 in % 1 in 3,700 Leukoencephalopathy with Vanishing EIF2B5 African 1 in % 1 in 2,300 99% White Matter (AR) East Asian 1 in % 1 in 8,200 NM_ Caucasian 1 in % 1 in 2,300 Latino 1 in % 1 in 2,000 South Asian 1 in % 1 in 7,600 Worldwide 1 in % 1 in 3,000
22 Limb-Girdle Muscular Dystrophy, Type 2A CAPN3 African 1 in % 1 in % (AR) Ashkenazi Jewish 1 in % 1 in 56,200 NM_ East Asian 1 in % 1 in 470 Finnish 1 in % 1 in 1,600 Caucasian 1 in % 1 in 720 Latino 1 in % 1 in 1,700 South Asian 1 in % 1 in 1,100 Worldwide 1 in % 1 in 770 Amish N/A 99% N/A Limb-Girdle Muscular Dystrophy, Type 2B DYSF African 1 in % 1 in % (AR) Ashkenazi Jewish 1 in % 1 in 440 NM_ East Asian 1 in % 1 in 1,000 Finnish 1 in % 1 in 2,400 Caucasian 1 in % 1 in 870 Latino 1 in % 1 in 700 South Asian 1 in % 1 in 570 Worldwide 1 in % 1 in 680 Sephardic Jewish - Libyan, 1 in 14 96% 1 in 330 Kavkazi and Yemenite Limb-Girdle Muscular Dystrophy, Type 2C SGCG African 1 in % 1 in 5,800 92% (AR) Caucasian 1 in % 1 in 4,900 NM_ Latino 1 in % 1 in 26,300 South Asian 1 in % 1 in 36,900 Worldwide 1 in % 1 in 8,000 Moroccan 1 in % 1 in 1,100 Roma 1 in 96 92% 1 in 1,200 Limb-Girdle Muscular Dystrophy, Type 2D SGCA African 1 in % 1 in 2,600 99% (AR) Ashkenazi Jewish 1 in % 1 in 27,500 NM_ East Asian 1 in % 1 in 8,400 Finnish 1 in % 1 in 25,600 Caucasian 1 in % 1 in 3,500 Latino 1 in % 1 in 7,800 South Asian 1 in % 1 in 5,000 Worldwide 1 in % 1 in 3,000 Limb-Girdle Muscular Dystrophy, Type 2E SGCB African 1 in % 1 in 32,600 98% (AR) East Asian 1 in % 1 in 71,800 NM_ Finnish 1 in % 1 in 105,000 Caucasian 1 in % 1 in 31,400 Latino 1 in % 1 in 168,000 South Asian 1 in % 1 in 18,600 Worldwide 1 in % 1 in 27,800 Limb-Girdle Muscular Dystrophy, Type 2I FKRP African 1 in % 1 in 3,300 99% (AR) Ashkenazi Jewish 1 in % 1 in 1,400 NM_ East Asian 1 in % 1 in 460 Finnish 1 in % 1 in 22,800 Caucasian 1 in % 1 in 1,300 Latino 1 in % 1 in 280 South Asian 1 in % 1 in 4,000 Worldwide 1 in % 1 in 880 Norwegian 1 in % 1 in 11,500
23 Lipoamide Dehydrogenase Deficiency (AR) DLD Ashkenazi Jewish 1 in 60 99% 1 in 5,900 99% NM_ East Asian 1 in % 1 in 225,000 Finnish 1 in % 1 in 70,400 Caucasian 1 in % 1 in 13,600 Latino 1 in % 1 in 3,300 South Asian 1 in % 1 in 118,000 Worldwide 1 in % 1 in 10,800 Lipoid Adrenal Hyperplasia (AR) STAR African 1 in % 1 in 10,800 99% NM_ East Asian 1 in % 1 in 36,300 Finnish 1 in % 1 in 6,300 Caucasian 1 in % 1 in 3,600 Latino 1 in % 1 in 2,400 South Asian 1 in % 1 in 7,400 Worldwide 1 in % 1 in 4,300 Lipoprotein Lipase Deficiency (AR) LPL African 1 in % 1 in 1,300 99% NM_ East Asian 1 in % 1 in 800 Caucasian 1 in % 1 in 2,400 Latino 1 in % 1 in 1,100 South Asian 1 in % 1 in 900 Worldwide 1 in % 1 in 1,600 French Canadian - Saguenay - 1 in 46 99% 1 in 4,500 Lac St. Jean French Canadian - Other 1 in % 1 in 13,800 Long-Chain 3-Hydroxyacyl-CoA HADHA African 1 in % 1 in 2,200 99% Dehydrogenase Deficiency (AR) East Asian 1 in % 1 in 4,600 NM_ Finnish 1 in % 1 in 12,200 Caucasian 1 in % 1 in 5,900 Latino 1 in % 1 in 7,100 South Asian 1 in % 1 in 73,200 Worldwide 1 in % 1 in 4,900 Lysinuric Protein Intolerance (AR) SLC7A7 African 1 in % 1 in 3,200 99% NM_ East Asian 1 in % 1 in 72,300 Finnish 1 in % 1 in 10,500 Caucasian 1 in % 1 in 3,000 Latino 1 in % 1 in 282,000 South Asian 1 in % 1 in 13,900 Worldwide 1 in % 1 in 5,100 Japanese 1 in % 1 in 980 Maple Syrup Urine Disease, Type 1a (AR) BCKDHA African 1 in % 1 in 1,600 98% NM_ Ashkenazi Jewish 1 in % 1 in 16,900 East Asian 1 in % 1 in 4,000 Finnish 1 in % 1 in 138,000 Caucasian 1 in % 1 in 5,100 Latino 1 in % 1 in 12,100 South Asian 1 in % 1 in 53,300 Worldwide 1 in % 1 in 5,700 Mennonite 1 in 10 98% 1 in 450 Portuguese Roma 1 in 71 98% 1 in 3,500
All diseases on Foresight
All diseases on Foresight Disease 11-Beta-Hydroxylase- Deficient Congenital Adrenal Hyperplasia 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia 3-Hydroxy-3-Methylglutaryl- CoA Lyase Deficiency
More informationBROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING.
BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING. The Inheritest SM Carrier Screen provides relevant genetic screening for many inherited diseases found throughout the pan-ethnic US population.
More informationCHRONIC MYELOGENOUS LEUKEMIA
CHRONIC MYELOGENOUS LEUKEMIA SHUFFLING THE GENETIC DECK IN CML 9 9 (q+) 22 Ph (22q-) bcr bcr-abl abl Fusion protein causes cancer GLEEVEC AND BCR-ABL FUSION PROTEIN GENETIC MEDICINE A. Genetic diseases
More informationForesight Carrier Screen
4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: 09/20/2017 Date Received: 09/22/2017 Date Tested: 09/27/2017 Indication:
More informationCLINICAL AND HUMAN TESTING
CLINICAL AND HUMAN TESTING CARRIER SCREENING FOR FAMILY PLANNING Let knowledge be your guide. Identify genetic conditions before or during a pregnancy to help predict the chances of having a child with
More informationForesight Carrier Screen
321 Main Street San Francisco, CA 94080 Phone: (415) 555-5555 Fax: (415) 555-5555 FE Sample Type: EDTA Blood Date of Collection: 07/12/2017 Date Received: 07/17/2017 Date Tested: 07/17/2017 Indication:
More informationForesight Carrier Screen
4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: Date Received: 02/19/2018 Date Tested: 02/26/2018 Accession ID: CSL3P6DMJ324JJ4
More informationForesight Carrier Screen
4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: 08/17/2017 Date Received: 08/18/2017 Date Tested: 08/24/2017 Indication:
More informationForesight Carrier Screen
321 Main Street San Francisco, CA 94080 Phone: (415) 555-5555 Fax: (415) 555-5555 FE Sample Type: OG-510 Saliva Date of Collection: 07/12/2017 Date Received: 07/17/2017 Date Tested: 07/17/2017 Indication:
More informationForesight Carrier Screen
Freiburg Medical Laboratory, ME LLC Box 3068 Dubai, 00000 Phone: +971 4 396 2227 FE Sample Type: EDTA Blood Date of Collection: 04/23/2018 Date Received: 04/27/2018 Date Tested: 05/05/2018 Indication:
More informationNutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:
NutraHacker Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d Instructions: In this report, NutraHacker examines single nucleotide polymorphisms that reveal carrier status
More informationForesight Carrier Screen
321 Main Street San Francisco, CA 94080 Phone: (415) 555-5555 Fax: (415) 555-5555 FE Sample Type: OG-510 Saliva Date of Collection: 06/23/2017 Date Received: 06/28/2017 Date Tested: 06/28/2017 Indication:
More informationEvolve FamilyReady Carrier Screen
Evolve FamilyReady Carrier Screen Accurate & Comprehensive Expanded Carrier Screen of >200 genes for the most relevant genetic disorders for all ethnicities. Achromatopsia CNGB3 X-linked Adrenoleukodystrophy
More informationHigh Impact Treatment Benefits X-Linked Moderate Impact. Disease Gene # Mutations Disease Group(s)
CarrierMap Expanded v3 Panel: 314 Diseases CarrierMap screen for 316 diseases including DMD. Disease Groups High Impact Treatment Benefits X-Linked Moderate Impact These diseases have a significant impact
More informationNextStep Carrier Screening
NextStep Carrier Screening What Is Carrier Screening? Certain genetic disorders occur more frequently in the general population, regardless of ethnic background. Carrier screening to determine if you and
More information4978 Santa Anita Ave Temple City, CA (p) (f)
Patient Information Doe, Jane Sex: F MR#: FD Patient#: FT-PT00000 Accession: FT-00000 Test#: FT-00000 Specimen Type: Blood (EDTA) Collection Date: Aug 01, 2017 Partner Information Not Tested Accession:
More informationCarrierMap. Genetic Counseling. Technology TABLE OF. Sample Report CONTENTS. New Offerings. Recombine Facts. Disease List
Recombine 2 CarrierMap 4 Genetic Counseling TABLE OF CONTENTS 8 12 14 Technology Sample Report New Offerings 18 Recombine Facts 19 Disease List CARRIERMA ROVIDES COMLETE We help families have healthy children
More informationThe Israeli population carrier screening program. Joël Zlotogora MD, PhD Hadassah medical school Hebrew University Jerusalem
The Israeli population carrier screening program Joël Zlotogora MD, PhD Hadassah medical school Hebrew University Jerusalem The Israeli population 2015 8,134,500 inhabitants Jews (75.1%) Ashkenazi, non
More information23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert
Table of contents Intended Use Important warnings and limitations Test performance User studies Specific test information 23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert For in-vitro
More informationComprehensive Jewish Carrier Screen
Comprehensive Jewish Carrier Screen What is carrier screening? There are several genetic disease mutations that occur at increased frequencies in the Ashkenazi Jewish (Central & Eastern European), Sephardi
More information23andMe Reports GENETIC HEALTH RISK REPORTS. Increased risk for breast and ovarian cancer. function
1 23andMe Reports GENETIC HEALTH RISK REPORTS BRCA1/BRCA2 Late-Onset Alzheimer's Disease Parkinson's Disease Age-Related Macular Degeneration Alpha-1 Antitrypsin Deficiency Celiac Disease G6PD Deficiency
More informationSAMPLE. Carrier Screening Results Report v2.2 Page 1/8
MM480: Pan-Ethnic Carrier Screen - Targeted Mutation Panel Report Prepared For: Patient: Name: Date of Birth: IDs (Internal / External): Reported Gender: Reported Ethnicity: Sample: Sample Collection Date:
More informationFamily Prep Screen POSITIVE: HIGH REPRODUCTIVE RISK. Cystic Fibrosis
123 Main Street Houston, TX 10231 Phone: (800) 555-1212 Fax: (800) 555-1212 FE Sample Type: OG-510 Saliva Date of Collection: 07/08/2014 Date Received: 07/13/2014 Date Tested: 07/13/2014 Indication: No
More informationJOHN DOE JANE DOE. Reproductive Risk Summary. Counsyl Test Results Summary
Results Recipient University Medical Center 827 Attn: Dr. Paul Smith 123 Main Street Houston, TX 10231 Phone: (800) 555-1212 Fax: (800) 555-1212 NPI: 7834324983 Report Date: 09/09/2013 Female Ethnicity:
More informationHERES Carrier Screening TEST
LISTADO DE ENFERMEDADES ANALIZADAS HERES Carrier Screening TEST 11-Beta-Hydroxylase-Deficient Congenital Adrenal Hyperplasia 17-Alpha-Hydroxylase Deficiency 17-Beta-Hydroxysteroid Dehydrogenase 3 Deficiency
More informationCARRIER SCREEN - LIST OF DISORDERS
1 11-Beta-Hydroxylase-Deficient Congenital Adrenal Hyperplasia 2 17-Beta-Hydroxysteroid deyhdrogenase X deficiency 3 2-Methylbutytyrglycinuria 4 21-hydroxylase deficiency 5 3-Methylcrotonyl-CoA carboxylase
More information23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert
Table of contents Intended Use Important warnings and limitations Test performance User studies Specific test information 23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert For in-vitro
More informationSema4 Natalis. Clinical significance of panel. Testing methods, sensitivity, and limitations
Sema4 Natalis Clinical significance of panel Sema4 has designed and validated Natalis, a supplemental newborn screening panel offered for newborns, infants, and young children. This test may be offered
More informationThe Counsyl Foresight Carrier Screen
The Counsyl Foresight Carrier Screen 180 Kimball Way South San Francisco, CA 94080 www.counsyl.com contact@counsyl.com (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient
More informationA Lawyer s Perspective on Genetic Screening Performed by Cryobanks
A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child
More informationUtility of Microarrays in Molecular Genetics
Utility of Microarrays in Molecular Genetics Madhuri Hegde, Ph.D., FACMG Associate Professor Senior Director Department of Human Genetics Emory Genetics Laboratory Emory University School of Medicine Atlanta,
More informationExpanded Carrier Screen (ECS)
Expanded Carrier Screen (ECS) What is carrier screening? Certain genetic disorders occur more frequently in the general population, regardless of ethnic background. Carrier screening to determine if you
More informationResults Recipient Ordering Healthcare Professional Male Details Female Details
Results Recipient Ordering Healthcare Professional Male Details Details Report Date /2010 Attn: Jessica Jacobson, MD Counsyl, Inc. 2200 Bridge Parkway, Suite 103 Redwood City, CA 94065 Phone: 1-888-COUNSYL
More informationPATIENT EDUCATION. carrier screening INFORMATION
PATIENT EDUCATION carrier screening INFORMATION carrier screening AT A GLANCE Why is carrier screening recommended? Carrier screening is one of many tests that can help provide information to you and your
More informationFurther expansion of the neonatal screening panel in the Netherlands
Further expansion of the neonatal screening panel in the Netherlands J.Gerard Loeber APHL-NBSGT, St.Louis (MO), USA 290216 Population Area Newborns 6.01 million 0.35:1 16.8 million 180,693 sq km 4.3:1
More informationKnowledge is power. Plan ahead with GeneAware.
MATERNAL FETAL Many patients may have questions regarding specific genetic disorders that may arise when planning or expecting a baby. That s why Baylor Genetics developed GeneAware, a reproductive carrier
More informationExpanded carrier screening for monogenic disorders: where are we now?
DOI: 10.1002/pd.5109 SPECIAL TOPIC ISSUE ON ADVANCES IN THE DIAGNOSIS OF SINGLE GENE DISORDERS Expanded carrier screening for monogenic disorders: where are we now? Davit Chokoshvili*, Danya Vears and
More informationGENE BY GENE CARRIER SCREENING
Patient Copy GENE BY GENE CARRIER SCREENING GENE BY GENE CARRIER SCREEN Various genetic mutations occur with increased frequencies in various ethnic groups in the United States and around the world. For
More informationCARRIER SCREENING PANEL
1 / 6 1. WHAT IS THE CARRIER? The carrier screening panel is a genetic test that simultaneously analyses mutations in 298 genes which cause recessive inherited pathologies. Diseases with a recessive inheritance
More informationShould Universal Carrier Screening be Universal?
Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden
More informationdisease carrier status PANEL DETAILS VERSION Risk Details JANE MILLER JOHN MILLER NEGATIVE CARRIER * NEGATIVE MILD CONDITION NEGATIVE
123 Main Street City, CA 10231 Phone: (800) 555-1212 Fax: (800) 555-1212 FE Sample Type: EDTA Blood Date of Collection: 02/06/2014 Date Received: 02/16/2014 Date Tested: 02/16/2014 Indication: Screening
More informationרשימת המחלות הנסקרות בבדיקה
רשימת המחלות הנסקרות בבדיקה By סקר גנטי טרום הריון - FamilyFirst בדיקת סקר גנטי טרום הריוני מורחב, הסוקרת כ- 850 מוטציות העלולות לחולל 255 מחלות תורשתיות. הבדיקה כוללת את כל המחלות המומלצות ע"י משרד הבריאות
More informationExpanded Carrier Screening: What s Best?
Expanded Carrier Screening: What s Best? James D Goldberg, MD September 17, 2017 Disclosures James D. Goldberg, M.D. Chief Medical Officer, Counsyl 3 Learning Objectives Guidelines Data Design Practice
More informationNewborn Screening: Focus on Treatment
Newborn Screening: Focus on Treatment Alan R. Fleischman, M.D. Senior Vice President and Medical Director March of Dimes National Conference of State Legislatures July 21, 2008 Newborn Screening: A Public
More informationOverview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy
Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy Alan R. Fleischman, M.D. Senior Vice President and Medical Director Chair, Federal Advisory Committee,
More informationSummary of Results CARRIER STATUS DNA INSIGHT. Result: Carrier, Heterozygote. Protected Health Information. Propionic Acidemia
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. SAPLE REPORT CARRIER STATUS DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Asian ORDERING HEALTHCARE PROFESSIONAL
More informationPositive Newborn Screens: What do you do next?
Positive Newborn Screens: What do you do next? James B. Gibson, MD, Ph.D. Biochemical Geneticist at Specially for Children Clinical Associate Professor of Pediatrics UTHSCSA Carla R. Scott, MD Pediatric
More informationNewborn Genetic Analysis
Fulgent tics Newborn tic Analysis Newborn tic Analysis (NGA) is a highly sophisticated and sensitive genetic test that identifies DNA changes that can cause infants to develop severe or life-altering conditions.
More informationTable S5. Disease pairs that have a significant comorbidity and are connected in either KEGG or BiGG database
Table S5. Disease pairs that have a significant comorbidity and are connected in either KEGG or BiGG database Coincide nce Expected coincidence Maximum possible comorbidity Disease1 Disease2 Link(KEGG)
More informationFor Your Baby s Health Department of Health
Newborn Screening For Your Baby s Health Department of Health Why is my baby tested? To help make sure your baby will be as healthy as possible. The blood test provides important information about your
More informationDiagnose a broad range of metabolic disorders with a single test, Global MAPS
PEDIATRIC Assessing or diagnosing a metabolic disorder commonly requires several tests. Global Metabolomic Assisted Pathway Screen, commonly known as Global MAPS, is a unifying test for analyzing hundreds
More information[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995
RULES AND REGULATIONS PERTAINING TO THE NEWBORN METABOLIC, ENDOCRINE, AND HEMOGLOBINOPATHY SCREENING PROGRAM AND THE NEWBORN HEARING LOSS SCREENING PROGRAM [R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE
More informationGenetic Carrier Screening
Genetic Carrier Screening Test Indications Carrier screening is a significant testing tool for inherited genetic conditions of prenatal care. The purpose of carrier screening is to identify couples at-risk
More informationCOMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS
COMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS S MELDAU, G VAN DER WATT INHERITED METABOLIC DISEASES GROUP UCT /
More informationNewborn Screening: Blood Spot Disorders
Newborn Screening: Blood Spot Disorders Arizona s Newborn Screening Program Program Overview Panel of Disorders Disorder Descriptions Program Components Hospitals ADHS Lab ADHS Follow-up ADHS Billing Medical
More informationTitle: Assessing Recommendations Related To Timeliness of Newborn Screening
Title: Assessing Recommendations Related To Timeliness of Newborn Screening Purpose: In January 2014, the Secretary s Discretionary Advisory Committee on Heritable Diseases on Newborns and Children (Committee)
More informationSequencing in Newborn Screening Introduction and Background
Sequencing in Newborn Screening Introduction and Background Suzanne Cordovado, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Centers for Disease Control and Prevention
More informationCenters for Medicare and Medicaid Services
Centers for Medicare and Medicaid Services Clinical Laboratory Fee Schedule Annual Laboratory Public Meeting June 25, 2018 Anthony Sireci, MD, Msc Association for Molecular Pathology Outline Germline Procedures
More information(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;
Ga. Comp. R. & Regs. r. 511-5-5-.02 Definitions Rule 511-5-5-.02. Definitions (a) "Abnormal test result" is a test result from blood testing or physiologic monitoring that is outside the screening limits
More informationBabyNEXT TM EXTENDED. Geni investigati e patologie associate. Gene Disease OMIM gene Familial hyperinsulinism ABCC8-related
Geni investigati e patologie associate BabyNEXT TM EXTENDED Gene Disease OMIM gene ABCC8 Familial hyperinsulinism ABCC8-related OMIM Disease Condition 600509 256450 Metabolic disorder - ABCD1 Adrenoleukodystrophy
More informationSperm Donor Profile. Asian American Indian African American/Black. Caucasian/White East Indian Latino/Hispanic
Sperm Donor Profile This packet is for informational purposes. All the questions have been answered by the donor and are unaltered with exception to the staff impressions, genetic screening results, and
More informationMISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
NEWBORN SCREENING Protecting your newborn MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES [ 1 ] NEWBORN SCREENING [ 2 ] FREQUENTLY ASKED QUESTIONS [ 4 ] DISORDERS INCLUDED IN NEWBORN SCREENING [ 12 ]
More informationA. disorders of amino acid metabolism classical phenylketonuria and hyperphenylalaninemia
OMIM # FULL NAME A. disorders of amino acid metabolism 1 261600 classical phenylketonuria and hyperphenylalaninemia 2 261640 phenylketonuria due to PTPS deficiency 3 261630 phenylketonuria due to DHPR
More informationPGD: A Celebration of 20 years:
PGD: A Celebration of 20 years: What is Reality and What is Not? Roma June 30, 2010 Mark Hughes, M.D., Ph.D. Professor of Genetics, Internal Medicine, Pathology Director, Genesis Genetics Institute Director,
More informationNewborn Screening in Manitoba. Information for Health Care Providers
Newborn Screening in Manitoba Information for Health Care Providers Newborn screening: a healthy start leads to a healthier life Health care professionals have provided newborn screening for phenylketonuria
More informationQUESTION. Personal Behavior History. Donor Genetic History. Donor Medical History. Family Medical History PERSONAL BEHAVIOR HISTORY. Never N/A.
Donor 4576 Medical Profile S Personal Behavior History Donor Genetic History Donor Medical History Family Medical History PERSONAL BEHAVIOR HISTORY Current alcohol use: If yes, oz./week and type of alcohol:
More informationMost common is the congenital adrenogenital syndrome (AGS) or congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
Newborn Screening Examination parameters: TSH-neonatal (hypothyreosis), 17-OH progesterone (AGS), galactose (galactosemia), galactose-uridyl transferase (galacto semia), biotinidase (biotinidase ), phenylalanine
More informationNewborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)
Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis) 1) Argininosuccinic acidemia (ASA) a) Incidence: ~1 in 70,000 b) Deficiency in an enzyme of
More informationCilioPathy panel. 3-Jul-2018 (102 genen) Centrum voor Medische Genetica Gent. versie. OMIM gene ID
versie 3-Jul-2018 (102 genen) CilioPathy panel Centrum voor Medische Genetica Gent Gene OMIM gene ID Associated phenotype, OMIM phenotype ID, phenotype mapping key and inheritance pattern AHI1 608894 Joubert
More informationA Guide for Prenatal Educators
A Guide for Prenatal Educators Why Teach Newborn Screening This booklet is designed to make it easy for you, a prenatal educator, to effectively inform expectant parents about newborn screening. All of
More informationNEWBORN SCREENING. health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
NEWBORN SCREENING health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES Table of Contents NEWBORN SCREENING...1 FREQUENTLY ASKED QUESTIONS...2 DISORDERS INCLUDED IN NEWBORN SCREENING...4
More informationWhole exome sequencing as a first line test: Is there even a role for metabolic biochemists in the future?
Whole exome sequencing as a first line test: Is there even a role for metabolic biochemists in the future? Tony Marinakii Purine Research Laboratory Biochemical Sciences Whole exome sequencing No doubt
More informationNewborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet
Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet Website:www.tipn.org.tw Telephone:(02)85962050 Ext. 401-403 Service line:(02)85962065 Fax:(02)85962067
More informationRoutine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015
Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015 Metabolic birth defects can cause physical problems, mental retardation and, in some cases, death. It is
More informationLABHORIZONS. New Procedures A NEWSLETTER FOR CLIENTS
LABHORIZONS A NEWSLETTER FOR CLIENTS Volume XVII, No. 7 July 2017 New Procedures 5 HIAA, Plasma.................................. 504510 CPT 83497 Synonyms 5-hydroxyindoleacetic acid Use Plasma 5-hydroxy-indoleacetic
More informationRelated Policies None
Medical Policy MP 2.04.107 BCBSA Ref. Policy: 2.04.107 Last Review: 04/30/2018 Effective Date: 04/30/0218 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationEVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW.
EVOLVE CARRIER GENETIC SCREENS Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW. PROTECT THE HEALTH OF YOUR FUTURE CHILDREN BY KNOWING YOUR GENETIC RISKS, TODAY! Carrier
More informationBeyond Mendel s Laws of Inheritance
Beyond Mendel s Laws of Inheritance 2006-2007 Extending Mendelian genetics Mendel worked with a simple system peas are genetically simple most traits are controlled by a single gene each gene has only
More informationORIGINAL RESEARCH ARTICLE
American College of Medical Genetics and Genomics Open An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals
More informationReproductive Physiology Primordial Germ Cells Yolk Sac Sex Chromosomes Females Males Sex-Linked Traits
Reproductive Physiology Primordial Germ Cells - from Yolk Sac these migrate to fetus when it is 5 weeks old - these cells give rise to the gonads (ovaries for female, testes for male) first they form the
More informationAccount # Notes. Physician Name Physician Phone Fax. Diagnosis. CLIA #38D Q11 REQ page 1 of 5
Knight Diagnostic Laboratories Fax: (855) 535-1329 Email: KDLClientServices@ohsu.edu Shipping: 2525 SW 3rd Ave, Ste 350, Portland, OR 97201 Questions? (855) 535-1522 Molecular Genetics Test Requisition
More informationNEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School
University of Massachusetts Medical School NEWBORN SCREENING in Massachusetts: Answers for You and Your Baby New England Newborn Screening Program Biotech 4, 2nd Floor UMass Medical School 377 Plantation
More informationStrand Neuromuscular Disorders Test: Genes & Test Selection
1 Strand Neuromuscular Disorders Test: Genes & Test Selection 2 Can the Strand Neuromuscular Disorders Test Be Offered for Prenatal Diagnosis? 3 Strand Neuromuscular Disorders Test: Genes & Test Selection
More informationOur partners worldwide. CENTOGENE Report: Diagnosed cases of rare diseases at CENTOGENE. January 2012 to June 2016.
CENTOGENE Report: cases of rare diseases at CENTOGENE January 202 to June 206 Elucidating the basis for the link between the clinical phenotype and genotype correlation, and the factors contributing to
More informationBULGARIAN NATIONAL PLAN. Associate professor Alexey Savov PhD National Consulting Council for Rare Diseases (NCCRD)
BULGARIAN NATIONAL PLAN FOR RARE DISEASES 2009 2013 Associate professor Alexey Savov PhD National Consulting Council for Rare Diseases (NCCRD) Strategy for rare diseases in Bulgaria Project of National
More informationGeneral Approach to Genetic Testing
Protocol General Approach to Genetic Testing (20491) Medical Benefit Effective Date: 01/01/17 Next Review Date: 11/18 Preauthorization Yes Review Dates: 01/11, 01/12, 09/12, 05/13, 09/13, 09/14, 09/15,
More informationAssessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory
Assessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory Bao Yang MPH Candidate Background The Wisconsin Newborn Screening (NBS) Laboratory screens 70,000 babies
More informationNEWBORN SCREENING. in Massachusetts: Information for You and Your Baby. University of Massachusetts Medical School
University of Massachusetts Medical School NEWBORN SCREENING in Massachusetts: Information for You and Your Baby New England Newborn Screening Program Biotech 4, 2nd Floor UMass Medical School 377 Plantation
More informationThe Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot
The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State Caroline T. Nucup-Villaruz, MD Primary Author NBS Consultant - Disorder FU Santosh Shaunak Co-Author & Presenter Laboratory
More informationUnifactorial or Single Gene Disorders. Hanan Hamamy Department of Genetic Medicine and Development Geneva University Hospital
Unifactorial or Single Gene Disorders Hanan Hamamy Department of Genetic Medicine and Development Geneva University Hospital Training Course in Sexual and Reproductive Health Research Geneva 2011 Single
More informationTIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN
TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN Susan Tanksley, PhD May 19, 2015 TIMELINESS - BACKGROUND In order to effectively
More informationGenetic Diseases. SCPA202: Basic Pathology
Genetic Diseases SCPA202: Basic Pathology Amornrat N. Jensen, Ph.D. Department of Pathobiology School of Science, Mahidol University amornrat.nar@mahidol.ac.th Genetic disease An illness caused by abnormalities
More informationBE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW.
BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. THE LEADER IN FERTILITY & REPRODUCTIVE GENETIC SCREENING EvolveGene was founded by world leaders in preventive and personalized healthcare, with over 25 years
More informationN.I.R.M.A.N. Dr. ANIL B. JALAN (MD DCH MCPS) Test list Oct 2017
Tests and Profiles Tests Method Sample Needed TAT Genetic Consultation / - All samples to be sent at 2 8 C. Counseling 1 Urine MRST - 15 ml Urine 24 hrs 2 Sr. Ammonia, Lactate, Sugar Fuji Dry Chem 2 ml
More informationLMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene
LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15
More informationGenetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report
Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report Roshanak Jazayeri, MD, PhD Assistant Professor of Medical Genetics Faculty of Medicine, Alborz University of Medical Sciences
More informationPREDICAGEN LLC REPORT
The report below is a scientific interpretation of the DNA variants (referred as RS numbers) to the customer by a third party (for example 23andMe). The report should not be considered exclusive, because
More informationNEWBORN METABOLIC SCREEN, MINNESOTA
Lab Dept: Test Name: Chemistry NEWBORN METABOLIC SCREEN, MINNESOTA General Information Lab Order Codes: Synonyms: CPT Codes: Test Includes: PKUN Newborn Screen for Hyopothyroidism, Phenylketonuria (PKU),
More informationQHerit Expanded Carrier Screen
QHerit Expanded Carrier Screen Test Code: 94372 (X) Specimen Requirements: Preferred: 6 ml (4 ml minimum) room-temperature whole blood: 1.5 ml (1 ml minimum) in each of 4 lavender-top (EDTA) or yellow-top
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is mandated and administered by the Illinois Department of
More information